Scientists AltSU took part in a major conference dedicated to tumor markers

4 August 2023 Department of Information and Media Communication

Employees of the Russian-American Anti-Cancer Center of Altai State University took part in the V All-Russian Conference with international participation "Tumor markers: molecular genetic and clinical aspects", which was held on the platform of the Regional Agro-Industrial Park of the Republic of Altai "AMZA" (the Republic of Altai, Maiminsky district, Mayma) from 26 to 29 of July, 2023.

This is a very significant and representative forum that brings together leading experts in the field of cancer research: practicing physicians, representatives of clinical diagnostics, as well as scientists – molecular biologists and geneticists.

The areas of the conference included the most important aspects of molecular genetic diagnosis in oncological practice, issues of oncopathology, biological markers, both used in the clinical diagnosis of oncological diseases and of fundamental importance, new approaches for the search and detection of biomarkers, as well as the challenges of modern cancer research.

“This is a very interesting event to be aligned and aware of the level of scientific developments throughout the country and even at the global level,” says Evgenia Kolosova, a junior researcher of RAACC. "Undoubtedly, the NGS technology (next generation sequencing) is the frontier trend in cancer research today. The overwhelming number of reports are built around this technology. In addition, there is a request from clinical oncology for geneticists who possess the NGS technology. There are very few such specialists today, in Altai Krai, I can say that I am the only one who has experience working with this technology, and the demand for them will grow annually.”

“The threshold for entry into this kind of research is very high, and, as a rule, those who do this self-organize in collaboration: on the one hand, these are clinical laboratories interested in genetic research of their samples, on the other hand, laboratories with sequencers and specialists, able to work for them. There is also a third party – bioinformatics, which allows processing the data flow,” explains Petr Kolosov, a senior researcher, acting director of RAACC.

Among the participants, there were such leading experts as Nikolai Kushlinsky, M.D., Professor, Academician of the Russian Academy of Sciences, Head of the Laboratory of Clinical Biochemistry of the National Medical Research Center of Oncology named after N.N. Blokhin, Ministry of Health of the Russian Federation, Evgeny Imyanitov, Corresponding Member of the Russian Academy of Sciences, M.D., Professor, Head of the Department of Biology of Tumor Growth of the N.N. Petrov Oncology Research Institute, Alexander Lazarev, M.D, Professor, Deputy Chairman of the Healthcare Committee of the Altai Regional Legislative Assembly.

The rich program of the conference included participants from the major centers of Moscow, St. Petersburg, Yekaterinburg, Omsk, Novosibirsk, Tomsk, Krasnoyarsk, Khabarovsk, and Vladivostok.

Evgeniy Imyanitov supported the idea of RAACC works dedicated to the development and production of recombinant oncoantigens, the panel of antigens for early cancer detection is a quite viable direction of scientific development, an import-substituting analogue of the Cancer SIG platform.

The joint work on the study of the characteristics of the immune response of patients with colorectal cancer will be continued by the specialists of the RAACC with the laboratory of Nikolai Kushlinsky.

Printable version